Dive deeper
Open any topic for the full explanation, tables, clinical checkpoints, and references.
Full-length video Where can I learn more about cutaneous squamous cell carcinoma?
What does a cSCC diagnosis mean?
What Does a Cutaneous Squamous Cell Carcinoma Diagnosis Mean?
Cutaneous squamous cell carcinoma is a cancer that begins in squamous cells in the outer part of the skin. “Cutaneous” simply means skin. You may also see the name shortened to cSCC, skin SCC, or squamous cell skin cancer.
Normal squamous cells help form the epidermis, the skin's outer layer. In invasive cSCC, abnormal squamous cells have crossed the boundary beneath the epidermis and entered deeper skin. That ability to invade is what makes it a cancer rather than only a surface change.
Most newly diagnosed cSCC is localized to the skin and can be treated effectively. A smaller group has features that raise the chance of local recurrence, nerve involvement, lymph-node spread, distant spread, or death from cSCC. The important question is not simply “Is this SCC?” It is “Which SCC is this, and what does its full risk picture show?”1–3
What does the cSCC pathology name mean?
What Does the Pathology Name Mean?
Three words do most of the work:
- Cutaneous identifies the organ: this began in the skin. It is not automatically the same disease as squamous cell carcinoma arising in the lung, mouth, cervix, or another organ.
- Squamous cell identifies the type of cell that became abnormal.
- Carcinoma means a malignant growth arising from lining cells. For invasive cSCC, the abnormal cells have entered tissue below the epidermis.
Actinic keratosis, SCC in situ, and invasive cSCC are different
| Diagnosis | What the name means | Can a photo settle it? | Usual next step |
|---|---|---|---|
| Actinic keratosis (AK) | A UV-related intraepidermal keratinocyte lesion. Typical/conventional AK usually does not span the full epidermal thickness; bowenoid/full-thickness AK nomenclature exists in some guidance, so pathology and clinical context matter. AK is not the same diagnosis as invasive cSCC.4,5 | No. AK can resemble SCC in situ, invasive cSCC, or a benign rough spot. | Clinical assessment and a lesion-appropriate plan; biopsy if the diagnosis or behavior is uncertain. |
| SCC in situ (Bowen disease) | Abnormal squamous cells involve the epidermis but have not crossed the basement-membrane boundary in the sampled tissue. “In situ” means confined in place.5 | No. A scaly plaque does not reveal whether an invasive focus is present. | A clinician selects an in-situ treatment. Surgery, destructive treatment, or a topical option may fit selected lesions; that evidence must not be transferred to invasive cSCC. |
| Invasive cSCC | Abnormal squamous cells have crossed into the dermis or deeper tissue. This creates the potential for deeper local growth and, in a minority of risk-defined tumors, spread beyond the skin.1,2,5 | No. Invasion is a microscopic diagnosis, not a visual guess. | Risk assessment followed by definitive treatment, usually surgery for localized disease. |
A partial biopsy can establish the right diagnosis while still missing a deeper or mixed feature elsewhere in the lesion. That is why the pathology result and the clinical examination must be read together.2
How common is cutaneous squamous cell carcinoma?
How Common Is cSCC?
cSCC is one of the most common cancers seen in dermatology, but a precise current United States annual count is difficult because many keratinocyte cancers are not captured in central cancer registries. A transparent local population rate is more honest than an impressive national number built on unstable assumptions.5,6,8
Evidence by the NumberscSCC is common in a defined population
cSCC is common in a defined population
162.5 per 100,000 person-years
- Population
- Residents of Olmsted County, Minnesota in a population-based cohort
- Outcome
- Age- and sex-adjusted incidence of new cSCC as ascertained in the cohort; the published report does not specify whether SCC in situ was excluded
- Time horizon
- January 2000 through December 2010
What it means: This is about 1.6 new cSCC tumors per 1,000 residents for each year of observation in that study population, supporting that cSCC is common.
Limitations: The population was older and predominantly White, the estimate is historical and local, and it is not a current United States annual count or an individual prediction.
References: 6
- Population and denominator: residents of Olmsted County, Minnesota; the published population-based cohort reported age- and sex-adjusted incidence rather than a current national count.
- Endpoint: age- and sex-adjusted incidence of new cSCC as ascertained in the cohort. The published report does not specify whether SCC in situ was excluded.
- Timeframe: January 2000 through December 2010.
- Result: 162.5 new cSCCs per 100,000 person-years.6
- Patient meaning: this is roughly 1.6 new cSCC tumors per 1,000 residents for each year of observation in that study population. It supports the simple point that cSCC is common.
- Limit: the county population was older and predominantly White, and the data are historical. This is not a current national rate and not an individual forecast.
Which factors raise cSCC risk?
What Causes cSCC, and Which Risk Factors Matter?
The main common driver is accumulated ultraviolet radiation from sunlight and tanning devices. UV injury builds over years, which is why cSCC is more common with increasing age and on chronically exposed areas. A single sunburn rarely explains a tumor by itself.2,5
Risk can also be higher with:
- skin that burns easily and a long history of sun damage, although cSCC occurs in every skin tone;
- previous actinic keratoses, cSCC, or other keratinocyte cancers;
- meaningful immune suppression, including solid-organ transplantation, certain blood cancers, stem-cell transplantation, HIV, or chronic immune-modifying medicine;
- prior radiation to the site;
- a chronic wound, scar, draining area, or long-standing inflammation;
- uncommon inherited conditions or carcinogen exposures assessed in the clinical history.1,2,5
Evidence by the NumbersFive-year outcomes separate sharply by cSCC risk group
Five-year outcomes separate sharply by cSCC risk group
0.1% vs 0.5% vs 10.5% cSCC-specific death
- Population
- 10,196 treated primary cSCC tumors in 8,727 patients at two US referral centers; mean age 72.4 years, 59.0% male, and 96.2% White
- Outcome
- Adjusted five-year cumulative incidence of local recurrence, nodal metastasis, distant metastasis, and cSCC-specific death across NCCN low-, high-, and very-high-risk tumors
- Time horizon
- Five years after treatment
What it means: The very-high-risk group had a materially different outcome pattern, so one pooled metastasis or mortality percentage is misleading and the risk label should guide care intensity.
Limitations: This was a retrospective referral-center cohort with tumors as the denominator; it is not a randomized trial, an individual calculator, or proof that a high-risk tumor has already spread.
References: 3
- Population and denominator: solid-organ transplant recipients across 67 population-based studies, compared with the reference populations used in those studies.
- Endpoint: incidence of cutaneous squamous cell carcinoma.
- Timeframe: study-specific follow-up in literature published through July 1, 2022; there was no single common follow-up duration.
- Result: pooled standardized incidence ratio 45.87 (95% CI, 31.70-66.38).7
- Patient meaning: as a group, solid-organ transplant recipients develop cSCC much more often, so prevention, early assessment, and coordinated follow-up matter.
- Limit: heterogeneity was extremely high (I² 99%), and individual study estimates ranged from about fivefold to more than 200-fold. Organ type, latitude, era, regimen, and time since transplant all matter. This is not a 46-fold prediction for one person and must not be applied to every form of immune suppression.7,9
Immune suppression changes the threshold for careful evaluation; it does not mean every spot is cancer or every cSCC will spread. Medication changes belong to the transplant or prescribing team, not to a patient acting alone.1,7,9
What can cSCC look or feel like?
What Can cSCC Look or Feel Like?
cSCC may appear as a firm bump, a thick or scaly growth, a crusted plaque, a sore that does not heal, or an area that bleeds with little trauma. It may be skin-colored, pink, red, brown, or pigmented. Some are tender; others cause no discomfort.2,5
cSCC occurs in every skin tone. In darker skin, a persistent lesion on a site that may not be chronically sun exposed—including the sole, around or under a nail, anogenital skin, or a chronic scar or wound—also deserves evaluation.15
No one appearance is diagnostic. A wart, irritated seborrheic keratosis, eczema, AK, SCC in situ, keratoacanthoma-like growth, and invasive cSCC can overlap visually. Skin tone, body site, lighting, camera focus, and surface crust can further mislead a photograph.
Clinical example: A rough forearm spot that slowly thickens might be an AK, SCC in situ, invasive cSCC, or a benign growth. The useful action is not to name it from an image; it is to note the change and obtain an in-person examination when it persists, grows, bleeds, hurts, or otherwise concerns you.
How can cSCC grow or spread?
How Does cSCC Grow or Spread?
The first direction of growth is usually local. Cancer cells can extend outward and downward beyond what is obvious at the surface. A neglected or aggressive tumor can damage skin, cartilage, muscle, bone, or nearby functional structures.
Three other routes matter in selected tumors:
- Along nerves: Perineural invasion means tumor is seen around or within a nerve. Microscopic nerve involvement and disease causing pain, numbness, tingling, weakness, or radiographic nerve spread are not the same finding.1,5
- To regional lymph nodes: A cSCC may reach the nodal basin that drains its body site—for example, neck nodes for many head-and-neck tumors, an armpit for an arm, or a groin for a leg.
- To distant organs: Distant metastasis can occur, especially in very-high-risk disease, but it is much less common than local disease. It should never be described with one percentage that mixes every risk group.3
Lower, high, and very-high risk
The risk label comes from the highest-risk feature present. This table is a teaching map, not a substitute for the full current guideline.1
| Risk pathway | Typical examples | What the label means | What it does not mean |
|---|---|---|---|
| Lower risk | Primary, well-defined tumor without high-risk clinical or pathology features; on the trunk or extremities, size 2 cm or smaller is lower risk by size/location; depth under 2 mm is lower risk by depth only when the tumor has not invaded beyond subcutaneous fat. | Several reliable local treatment approaches may fit after the complete picture is reviewed. | “Harmless,” “no treatment needed,” or “zero chance of recurrence.” |
| High risk | One or more features such as a higher-risk site/size, recurrence, poor definition, rapid growth, neurologic symptoms, immune suppression, prior radiation/chronic inflammation, adverse histology, or depth 2-6 mm without invasion beyond subcutaneous fat. On the trunk or extremities, tumors larger than 2 cm through 4 cm inclusive are high risk by size/location. The head, neck, hands, feet, pretibia, and anogenital area are high-risk locations at any size. | The chance of an adverse outcome is higher; stronger margin control, nodal attention, or closer follow-up may be appropriate. | Proof that cancer is in a lymph node or another organ. |
| Very high risk | Examples include diameter over 4 cm at any site, depth over 6 mm or invasion beyond subcutaneous fat (including bone), clinically significant nerve involvement, lymphovascular invasion, or other current very-high-risk criteria. | A more intensive local and regional plan is often needed, sometimes with imaging or multidisciplinary care. | A synonym for metastatic, incurable, or fatal disease. |
Size alone cannot settle the category. A small tumor can still be serious because of location, recurrence, depth, differentiation, nerve involvement, immune status, or another feature. Conversely, a pathology word should not be interpreted without the entire tumor and patient context.1
Evidence by the NumbersSolid-organ transplantation changes population cSCC incidence
Solid-organ transplantation changes population cSCC incidence
Pooled SIR 45.87 (95% CI, 31.70-66.38)
- Population
- Solid-organ transplant recipients across 67 population-based studies compared with the reference populations used in those studies
- Outcome
- Standardized incidence ratio for cutaneous squamous cell carcinoma
- Time horizon
- Study-specific follow-up in literature published through July 1, 2022; no single common duration
What it means: Transplant recipients develop cSCC far more often as a group, supporting earlier prevention, assessment, and coordinated follow-up.
Limitations: Heterogeneity was extreme (I² 99%); individual study estimates ranged from about fivefold to more than 200-fold. The pooled result is not one person's multiplier and cannot be transferred to every immune-suppressed population.
| Five-year endpoint | Low-risk tumors | High-risk tumors | Very-high-risk tumors |
|---|---|---|---|
| Local recurrence | 0.8% | 1.5% | 9.4% |
| Nodal metastasis | 0.1% | 0.5% | 7.3% |
| Distant metastasis | 0.01% | 0.1% | 3.9% |
| Death from cSCC | 0.1% | 0.5% | 10.5% |
- Population: treated patients with primary cSCC; mean age 72.4 years, 59.0% male, and 96.2% White.
- Denominator: tumors, not people; one person could contribute more than one tumor.
- Endpoints and timeframe: adjusted cumulative incidence of local recurrence, nodal metastasis, distant metastasis, and cSCC-specific death within five years.
- Patient meaning: the very-high-risk group had a markedly different outcome pattern. That is why one pooled spread or death rate is misleading.
- Limit: this was an observational referral-center cohort, not a randomized trial or a prediction calculator. Your category and outcome require your own pathology, examination, treatment, and health context.3
What happens if cSCC is untreated, and how urgent is it?
What Can Happen If It Is Untreated, and How Urgent Is It?
Untreated invasive cSCC can continue to enlarge, ulcerate, bleed, cause pain, invade deeper structures or nerves, and reach lymph nodes or, less commonly, distant organs. There is no ethical study in which invasive cSCC is deliberately left untreated to create one reliable countdown. Growth rates and consequences vary too much to promise either “you have plenty of time” or “this is an emergency.”1,2,5
For most localized diagnoses, the right frame is prompt outpatient planning, not panic and not indefinite delay.
| Finding or situation | What it may mean | Useful next action |
|---|---|---|
| New biopsy-proven cSCC with no major new symptoms | A treatment plan is needed, but the diagnosis alone usually does not require an emergency department visit. | Keep or arrange the follow-up promptly; obtain the pathology report and confirm the exact site. |
| Rapid enlargement, persistent bleeding, increasing pain, or a repeatedly breaking-down lesion | The tumor may be clinically active or affecting deeper tissue; another condition could also contribute. | Contact the treating clinician promptly and describe what changed. |
| New numbness, tingling, burning pain, weakness, facial asymmetry, or another focal nerve symptom near the tumor | Possible nerve involvement or another neurologic problem; the symptom does not prove perineural spread. | Promptly contact the treating team; ask whether the evaluation should be expedited and whether nerve-focused examination or imaging is needed. |
| A new firm or enlarging lump in the nearby neck, armpit, groin, or other draining nodal area | A reactive node and metastatic disease can both cause a lump; examination is needed. | Prompt clinician contact for nodal examination and risk-directed testing. |
| Uncontrolled bleeding or sudden loss of an important function | An acute problem that requires immediate stabilization, regardless of the cause. | Seek urgent or emergency care. |
Clinical example: Two patients can both have a 1-centimeter cheek cSCC. Both are already high risk by location. One has a well-defined shallow primary tumor and no symptoms. The other is immune-suppressed and reports new facial numbness, adding further high-risk features and changing the urgency and the questions the team must answer. Those features still do not prove that the cancer has spread.
How is cSCC diagnosed?
How Is cSCC Diagnosed?
A clinician examines the lesion, asks how it changed, reviews risk context, and takes a biopsy that is wide and deep enough for the clinical question. Common approaches include shave, punch, and excisional biopsy; the best choice depends on the lesion, site, and suspected depth.2
A pathologist then examines the tissue under a microscope. Useful report details can include:
- In situ or invasive: whether tumor is confined to the epidermis or has crossed into deeper skin;
- Differentiation: how closely the tumor cells resemble normal squamous cells; poor differentiation can raise risk;
- Depth or level of invasion: how far the sampled tumor extends;
- Perineural invasion: tumor around or within a nerve, with significance depending on nerve size, extent, symptoms, and imaging;
- Lymphovascular invasion: tumor within lymphatic or blood vessels, an adverse feature but not proof of a diagnosed metastasis;
- Margins: whether tumor touches an examined cut edge of the submitted specimen;
- Subtype and other features: findings that may change risk or treatment.
The biopsy margin trap
A diagnostic biopsy is not always designed or oriented as definitive margin surgery. “Margins negative” means tumor was not seen at the examined edges of the submitted sample. A negative diagnostic-biopsy margin alone cannot prove clearance: residual tumor can still exist outside that sample or deeper in the clinical site. Definitive management depends on the procedure's intent, what remains at the clinical site, the pathology findings, and the tumor's complete risk profile.2,13,14
If the sample is too superficial or the pathology and clinical behavior do not fit, a deeper or repeat sample, review of slides, or definitive excision may add information. That does not make the first biopsy useless; it defines the boundary of what it sampled.2
How is cSCC treated, and what affects prognosis?
How Is It Treated, and What Is the Prognosis?
For localized invasive cSCC, surgery is the main treatment for most patients. The operation and margin method should match tumor risk, anatomy, function, and the cost of recurrence.1,2
| Clinical setting | High-level treatment map | Where to continue |
|---|---|---|
| SCC in situ | Surgery, a destructive method, or a topical/field treatment may fit selected lesions. These choices do not automatically apply to invasive cSCC. | Review the exact pathology and an in-situ-specific plan with the treating clinician. |
| Lower-risk localized invasive cSCC | Standard excision is often appropriate; Mohs/PDEMA or selected other local treatment may fit specific anatomy and tumor features. | Squamous Cell Carcinoma Treatment Options |
| High- or very-high-risk localized cSCC | Complete mapped margin assessment is often favored; nodes, nerves, imaging, radiation, and multidisciplinary review enter when the risk pattern calls for them. | Low-Risk vs High-Risk Skin Cancer and Squamous Cell Carcinoma Treatment Options |
| cSCC during transplant or other meaningful immune suppression | The local tumor and the underlying immune condition both shape treatment and follow-up. Medication changes require the prescribing or transplant team. | High-Risk SCC in Transplant and Immunosuppressed Patients |
| Surgery is not feasible or disease extends beyond a local surgical problem | Radiation and PD-1 immunotherapy can enter selected plans; advanced disease requires multidisciplinary sequencing rather than one universal procedure.1,10–12 | Use the treatment article and the treating multidisciplinary team. |
Many appropriately treated localized tumors have a favorable prognosis. The Stevens cohort shows why that statement needs a second sentence: very-high-risk tumors had substantially higher five-year recurrence, metastasis, and cSCC-specific death than lower-risk tumors.3 Prognosis is therefore risk-specific, treatment-dependent, and personal; it should not be reduced to one reassuring or frightening percentage.
What should I ask or do next about cSCC?
What Should I Ask or Do Next?
- Verify the site and exact words. Ask for a copy of the pathology report and confirm that the body site matches the biopsied spot.
- Ask whether it is in situ or invasive. If invasive, ask which pathology and clinical features define the risk category.
- Name the risk modifiers. Tell the clinician about transplant history, blood cancer, HIV, immune-modifying medicines, prior radiation, chronic wounds/scars, earlier skin cancers, rapid growth, recurrence, and nerve symptoms.
- Ask about examination beyond the spot. Were the relevant nearby lymph nodes examined? Do the risk features or symptoms justify imaging? Most lower-risk tumors do not need automatic scans.1,5
- Understand the treatment goal and margin method. Ask why the proposed treatment fits this risk and site, how margins will be assessed, and what would change the plan.
- Clarify timing in your context. Ask what “prompt” means for this specific tumor and which changes should trigger an earlier call.
- Do not change immune medicine alone. If a medication change is considered, ask how dermatology, oncology, and the transplant or prescribing team will coordinate it.
Frequently asked questions about cSCC
Frequently Asked Questions
Is cSCC the same as squamous cell carcinoma in another organ?
No. “Cutaneous” identifies a cancer that began in the skin. Squamous cell carcinomas in the lung, mouth, cervix, and other organs have different staging and treatment systems.
Is cSCC contagious?
No. You cannot catch cSCC by touching it or sharing space with someone who has it.
Does SCC in situ spread to lymph nodes?
A lesion that is truly confined to the epidermis has not invaded the structures needed for metastasis. The important qualifier is sampling: a partial biopsy can occasionally miss an invasive focus elsewhere, which is why the report and clinical lesion must agree.2,5
If my cSCC is high risk, does that mean it already spread?
No. High risk describes a higher probability and a need for a more deliberate plan. Metastasis is a separate finding established by examination, imaging, or tissue diagnosis when indicated.1,3
Does a negative margin on a diagnostic biopsy prove that the entire tumor is cleared?
No—a negative margin on a diagnostic biopsy alone does not prove that the entire clinical tumor has been cleared. Definitive management depends on the procedure's intent, what remains at the clinical site, the pathology findings, and the tumor's complete risk profile. Ask the treating clinician whether the biopsy was intended as definitive treatment and what, if anything, remains to be done.2,13,14
How quickly do I need treatment?
Most localized cSCC is handled through prompt outpatient planning rather than emergency care, but there is no universal safe waiting period. Risk features, site, immune status, growth, bleeding, nerve symptoms, and nodal findings can change timing. Ask the treating team for a tumor-specific timeframe.
Should I stop an immune-suppressing medicine?
Not on your own. The safest cancer plan can be unsafe for a transplanted organ or underlying disease if medicines are changed without the prescribing team.1,7,9
Can a photograph or app tell me whether a spot is invasive?
No. An image can help document change or support triage, but invasion is determined by examining adequate tissue under a microscope.2,5
Where should I go next in the cSCC Patient Journey?
Next Steps in the Patient Journey
Continue with the question that best fits what you know now. Your dermatologist or treating team can apply the complete pathology and examination to your situation.
Continue with the question that fits you now
Who reviewed and authored this cSCC guide?
References for this cSCC guide
References
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Squamous Cell Skin Cancer. Version 2.2026. Updated March 17, 2026.
- Kim JYS, Kozlow JH, Mittal B, Moyer J, Olenecki T, Rodgers P. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78(3):560-578. doi:10.1016/j.jaad.2017.10.007.
- Stevens JS, Murad F, Smile TD, et al. Validation of the 2022 National Comprehensive Cancer Network risk stratification for cutaneous squamous cell carcinoma. JAMA Dermatol. 2023;159(7):728-735. doi:10.1001/jamadermatol.2023.1353.
- Eisen DB, Asgari MM, Bennett DD, et al. Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2021;85(4):e209-e233. doi:10.1016/j.jaad.2021.02.082.
- Stratigos AJ, Garbe C, Dessinioti C, et al. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention—Update 2023. Eur J Cancer. 2023;193:113251. doi:10.1016/j.ejca.2023.113251.
- Muzic JG, Schmitt AR, Wright AC, et al. Incidence and trends of basal cell carcinoma and cutaneous squamous cell carcinoma: a population-based study in Olmsted County, Minnesota, 2000 to 2010. Mayo Clin Proc. 2017;92(6):890-898. doi:10.1016/j.mayocp.2017.02.015.
- Jin F, Vajdic CM, Poynten IM, McGee-Avila JK, Castle PE, Grulich AE. Cancer risk in people living with HIV and solid organ transplant recipients: a systematic review and meta-analysis. Lancet Oncol. 2024;25(7):933-944. doi:10.1016/S1470-2045(24)00189-X.
- Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68(6):957-966. doi:10.1016/j.jaad.2012.11.037.
- Gjersvik P, Falk RS, Roscher I, et al. Rates of second tumor, metastasis, and death from cutaneous squamous cell carcinoma in patients with and without transplant-associated immunosuppression. JAMA Dermatol. 2023;159(9):923-929. doi:10.1001/jamadermatol.2023.2029.
- Gross ND, Miller DM, Khushalani NI, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. 2022;387(17):1557-1568. doi:10.1056/NEJMoa2209813.
- Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020;21(2):294-305. doi:10.1016/S1470-2045(19)30728-4.
- Krausz AE, Ji-Xu A, Smile T, et al. A systematic review of primary, adjuvant, and salvage radiation therapy for cutaneous squamous cell carcinoma. Dermatol Surg. 2021.
- Purnell JC, Duncan JR, Stratton MS, Huang C, Phillips CB. Negative predictive value of biopsy margins in keratinocyte carcinoma: a literature review. Dermatol Surg. 2020;46(4):525-529. doi:10.1097/DSS.0000000000002171.
- Schnebelen AM, Gardner JM, Shalin SC. Margin status in shave biopsies of nonmelanoma skin cancers: is it worth reporting? Arch Pathol Lab Med. 2016;140(7):678-681.
- Wysong A. Squamous-cell carcinoma of the skin. N Engl J Med. 2023;388(24):2262-2273. doi:10.1056/NEJMra2206348.